Strategies for the diagnosis and treatment of pulmonary chronic graft-versus-host disease after hematopoietic stem cell transplantation
10.3760/cma.j.cn121090-20250128-00048
- VernacularTitle:造血干细胞移植后肺部慢性移植物抗宿主病的诊疗策略
- Author:
Chunrong JU
1
;
Shunqing WANG
;
Xi ZHANG
;
Qifa LIU
Author Information
1. 广州医科大学附属第一医院器官移植科，广州呼吸健康研究院，国家呼吸医学中心 国家呼吸系统疾病临床医学研究中心 呼吸疾病国家重点实验室，广州 510120
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(8):771-778
- CountryChina
- Language:Chinese
-
Abstract:
Hematopoietic stem cell transplantation (HSCT) is currently an effective method to cure hematologic malignancies and bone marrow failure diseases, and can restore hematopoietic function destroyed by hematologic malignant diseases. In recent years, HSCT has developed rapidly in China, but pulmonary chronic graft-versus-host disease after transplantation has seriously affected the quality of life and long-term survival of patients. Therefore, this article aims to describe the risk factors, clinical classification, and early diagnosis and treatment strategies of pulmonary chronic graft-versus-host disease, and proposes that lung transplantation is the only effective therapeutic intervention when medical treatment proves ineffective for end-stage pulmonary cGVHD.
